Eyepoint Pharmaceuticals announced results for its Phase 2 PAVIA clinical trial for the potential treatment of non-proliferative diabetic retinopathy and posted an updated investor presentation on its website.
AI Assistant
EYEPOINT PHARMACEUTICALS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.